glp 1 study GLP-1 Receptor Agonists as Treatments for Type 2 Diabetes Now, new research suggests that
Description
Stop at first signs of fullness
SAXENDAKey Asset in Novo Nordisk Obesity Market Novo Nordisk weight loss drug, SAXENDA (liraglutide), is a GLP-1 receptor agonist designed to support long-term weight loss when combined with a reduced-calorie diet and increased physical activity

Most insurance plans cover Ozempic for type 2 diabetes and not for weight loss, although it depends on the specific insurance plan

Last reviewed: June 29, 2026 Last updated: June 29, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations

Her instagram will walk you through workouts & healthy recipes